Summary statement: utility of molecular marker testing in thyroid cancer.
The use of molecular markers for thyroid cancer diagnosis, prognosis, and surveillance have been an exciting area of study and change. Recent investigative focus on promising new markers will very likely lead to improvements in the diagnostic utility of fine needle aspiration biopsy (FNAB) in predicting malignancy, as well as provide more accurate prognostic information pre- and postoperatively. The 2010 Annual Meeting of the American Association for Endocrine Surgeons featured a symposium dedicated to molecular marker testing in thyroid cancer and its potential clinical applicability.
Division of Endocrine Surgery, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. yipl@upmc.edu
Linwah
L
Yip
Electron
E
Kebebew
Mira
M
Milas
Sally E
SE
Carty
Thomas J
TJ
Fahey
Sareh
S
Parangi
Martha A
MA
Zeiger
Yuri E
YE
Nikiforov
D042702:Angiopoietin-2 / Q000235:genetics; D044963:Biopsy, Fine-Needle / Q000379:methods* / Q000592:standards; D018076:DNA, Complementary / Q000235:genetics; D015321:Gene Rearrangement; D011905:Genes, ras; D005819:Genetic Markers / Q000235:genetics*; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000235:genetics
D042702:Angiopoietin-2; D018076:DNA, Complementary; D005819:Genetic Markers; D012333:RNA, Messenger; D019715:Tissue Inhibitor of Metalloproteinase-1; D013954:Thyroglobulin